Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

AbbVie has shared promising top-line results from a late-stage study of its JAK inhibitor Rinvoq (upadacitinib) in severe ...

Key opinion leaders (KOLs) interviewed by GlobalData have expressed the need for therapies with higher efficacy to improve ...

US pharma major AbbVie recently announced top-line results from one of two parallel studies of the pivotal Phase III UP-AA ...

Upadacitinib demonstrated significant efficacy in promoting scalp hair regrowth in severe alopecia areata patients, achieving primary endpoints in nearly half of the participants. The phase 3 trials ...

This patient in his late teens presented with a one week history of a widespread painful rash, accompanied by fever and fatigue. Two weeks previously he had started oral upadacitinib—a Janus kinase ...

Strong efficacy and safety perceptions, as well as favorable administration fuel utilization of the IL-23 class in Crohn's disease, according to Sphe ...

The UP-AA clinical program includes 2 studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.

The Crohn’s disease (CD) treatment landscape is undergoing a radical transformation as newer mechanisms of action (MOAs), particularly IL-23 inhibitors and JAK ...

In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in ...